Abstract

The current lack of a reliable biomarker of disease activity in anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis poses a significant clinical unmet need when determining relapsing or persisting disease. In this study, we demonstrate for the first time that attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy offers a novel and functional candidate biomarker, distinguishing active from quiescent disease with a high degree of accuracy. Paired blood and urine samples were collected within a single UK centre from patients with active disease, disease remission, disease controls and healthy controls. Three key biofluids were evaluated; plasma, serum and urine, with subsequent chemometric analysis and blind predictive model validation. Spectrochemical interrogation proved plasma to be the most conducive biofluid, with excellent separation between the two categories on PC2 direction (AUC 0.901) and 100% sensitivity (F-score 92.3%) for disease remission and 85.7% specificity (F-score 92.3%) for active disease on blind predictive modelling. This was independent of organ system involvement and current ANCA status, with similar findings observed on comparative analysis following successful remission-induction therapy (AUC > 0.9, 100% sensitivity for disease remission, F-score 75%). This promising technique is clinically translatable and warrants future larger study with longitudinal data, potentially aiding earlier intervention and individualisation of treatment.

Details

Title
Distinguishing active from quiescent disease in ANCA-associated vasculitis using attenuated total reflection Fourier-transform infrared spectroscopy
Author
Morris, Adam D 1 ; Morais Camilo L M 2 ; Lima, Kássio M, G 3 ; Freitas Daniel L D 3 ; Brady, Mark E 1 ; Dhaygude, Ajay P 1 ; Rowbottom, Anthony W 4 ; Martin, Francis L 5 

 Royal Preston Hospital, Lancashire NHS Foundation Trust, Department of Renal Medicine, Preston, UK (GRID:grid.416204.5) (ISNI:0000 0004 0391 9602) 
 University of Central Lancashire, School of Pharmacy and Biomedical Sciences, Preston, UK (GRID:grid.7943.9) (ISNI:0000 0001 2167 3843) 
 Federal University of Rio Grande Do Norte, Institute of Chemistry, Biological Chemistry and Chemometrics, Natal, Brazil (GRID:grid.411233.6) (ISNI:0000 0000 9687 399X) 
 Royal Preston Hospital, Lancashire NHS Foundation Trust, Department of Immunology, Preston, UK (GRID:grid.416204.5) (ISNI:0000 0004 0391 9602); University of Central Lancashire, School of Medicine, Preston, UK (GRID:grid.7943.9) (ISNI:0000 0001 2167 3843) 
 Biocel UK Ltd, Hull, UK (GRID:grid.7943.9) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2525225576
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.